VICP Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (22 Apr 2024 @ 14:40):

Stats
Today's Volume	100.00
Average Volume	63.00
Market Cap	25.50M
EPS	$-0.00699 ( 2023-09-29 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-32.66
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2010-09-03	Yurkowski Michael	Sell	5 000	SSGI
2010-08-09	Yurkowski Michael	Sell	20 000	Common Stock
2010-05-13	Moore Bobby M Jr	Sell	0	Common Stock
2010-01-26	Yurkowski Michael	Sell	5 000	SSGI
2010-01-14	Yurkowski Michael	Sell	5 000	Common Stock

INSIDER POWER
0.00
Last 19 transactions
Buy: 0 \| Sell: 1 754 181

Vicapsys Life Sciences, Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Vicapsys Life Sciences, Financials

Annual	2022
Revenue:	$0
Gross Profit:	$-31 288.00 (0.00 %)
EPS:	$-0.0545

Q3	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.00700

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.00380

Q1	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.00610

Financial Reports:

No articles found.

Vicapsys Life Sciences,

Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN proprietary product. Its product is applied to transplantation therapies and related stem-cell applications in the transplantation field. The company is also developing VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics International, Inc. and changed its name to Vicapsys Life Sciences, Inc. in September 2017. Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Suwanee, Georgia.